Fundraising FoxOncorena
Stockholm, SE · 3 known investors
Find your way into Oncorena
Sign up to see every warm intro you have to Oncorena
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oncorena team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine). The company targets an orphan drug indication with clinical development underway.
Founders & leadership
BH
Börje HaraldssonResearch leadBörje Haraldsson trained as a nephrologist and holds academic qualifications in medical physics, physiology, and nephrology. He previously served as Global Program Head at Novartis leading international drug development teams, and has held leadership positions in academic and hospital settings.
UN
Ulf Nilsson
SD
Susanna DahlgrenChief Operating OfficerChief Operating Officer of Oncorena, a Swedish pharmaceutical company developing treatments for renal cancer. Dahlgren brings over 15 years of pharmaceutical development experience spanning research, project management, and medical affairs across drug discovery through regulatory approval and launch phases, with deep expertise in immunology and inflammation.
HX
Hanjing XieHanjing Xie is an oncologist with over 25 years of clinical experience across multiple cancer types and board certification in clinical oncology, internal medicine, and hematology, alongside a PhD in Clinical Pharmacology from Karolinska Institute where he serves as Associate Professor of Oncology. He has held senior positions in Medical Affairs and Clinical Development at both large pharmaceutical and biotech companies since 2015, with extensive experience in clinical trial design, execution, and regulatory submissions to FDA and EMA.
AS
Ann-Kristin SpiikAnn-Kristin Spiik is the founder of Oncorena, a Swedish pharmaceutical company developing treatment for metastatic renal cancer. She has expertise in pharmaceutical development, regulatory affairs, clinical supply chain management, and quality documentation across multiple therapeutic areas.
CL
Christer Lundell-Ek
ÅH
Åsa HolmgrenHead of Regulatory Affairs
Investors · 3
HealthCap✓ confirmed by OncorenaStockholm
How we know: the company's own site · HealthCap's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Oncorena do?
- Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine). The company targets an orphan drug indication with clinical development underway.
- Who founded Oncorena?
- Oncorena was founded by Börje Haraldsson, Jenny Nyström, Ulf Nilsson, Lisa Buvall.
- Who are Oncorena's investors?
- Oncorena's investors include HealthCap, FSG, GU Ventures AB.
- Where is Oncorena headquartered?
- Oncorena is headquartered in Stockholm, SE.